FY2024 EPS Estimate for Silence Therapeutics Cut by Analyst

Silence Therapeutics plc (NASDAQ:SLN) – Analysts at HC Wainwright decreased their FY2024 earnings estimates for shares of Silence Therapeutics in a research note issued on Wednesday, January 29th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($1.73) for the year, down from their prior forecast of ($1.60). HC Wainwright currently has a “Buy” rating and a $75.00 target price on the stock. The consensus estimate for Silence Therapeutics’ current full-year earnings is ($1.77) per share. HC Wainwright also issued estimates for Silence Therapeutics’ Q4 2024 earnings at ($0.41) EPS, Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.53) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($2.30) EPS, FY2026 earnings at ($2.56) EPS, FY2027 earnings at ($2.28) EPS and FY2028 earnings at ($0.41) EPS.

Other research analysts also recently issued reports about the company. William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a report on Tuesday, November 19th. Morgan Stanley reiterated an “overweight” rating and set a $49.00 target price on shares of Silence Therapeutics in a research report on Tuesday, October 8th. BMO Capital Markets restated an “outperform” rating on shares of Silence Therapeutics in a report on Monday, December 2nd. Finally, Chardan Capital reiterated a “buy” rating and set a $55.00 price objective on shares of Silence Therapeutics in a report on Tuesday, December 10th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $54.75.

Silence Therapeutics Price Performance

Shares of SLN opened at $5.61 on Monday. Silence Therapeutics has a 1-year low of $4.82 and a 1-year high of $27.72. The stock has a market cap of $167.90 million, a price-to-earnings ratio of -3.57 and a beta of 1.08. The firm has a 50 day simple moving average of $6.52 and a 200-day simple moving average of $13.52.

Hedge Funds Weigh In On Silence Therapeutics

Large investors have recently bought and sold shares of the business. Values First Advisors Inc. bought a new stake in Silence Therapeutics during the 3rd quarter valued at $56,000. Y Intercept Hong Kong Ltd raised its stake in shares of Silence Therapeutics by 22.9% during the third quarter. Y Intercept Hong Kong Ltd now owns 21,078 shares of the company’s stock valued at $383,000 after purchasing an additional 3,923 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Silence Therapeutics by 609.2% in the fourth quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock worth $42,000 after purchasing an additional 5,233 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in Silence Therapeutics in the 4th quarter valued at about $69,000. Finally, Verition Fund Management LLC bought a new position in Silence Therapeutics in the 3rd quarter valued at about $207,000. Institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.